Azabicyclic heterocycles as cannabinoid receptor modulators

US7378418B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Guixue Yu · Wakefield, US
• William R. Ewing · Yardley, US
• Amarendra B. Mikkilineni · Easton, US
• Annapurna Pendri · South Glastonbury, US
• Philip M. Sher · Plainsboro, US
• Samuel Gerritz · Guilford, US
• Bruce A. Ellsworth · Princeton, US
• Gang Wu · Zhejiang, CN
• Yanting Huang · Pennington, US
• Chongqing Sun · Plainsboro, US
• Natesan Murugesan · Lawrenceville, US
• Zhengxiang Gu · Princeton, US
• Ying Wang · Chengdu, CN
• Doree F. Sitkoff · Dresher, US
• Stephen R. Johnson · Erdenheim, US
• Ximao Wu · Princeton Junction, US

Key dates

• Filing date: Dec 17, 2004
• Grant date: May 27, 2008
• Expiry date: Jun 24, 2025

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I:including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, R6, R7, m and n are described herein.